Pyxis Oncology is engaged in the development of therapeutics to treat cancers. Co. develops its product candidates to kill tumor cells and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion. Co. has developed a portfolio of antibody drug conjugate product candidates and monoclonal antibody (mAb) preclinical discovery programs that it is developing as monotherapies and in combination with other therapies. Co.'s product candidates, PYX-201 and PYX-202 are in IND-enabling studies. In addition, PYX-203 is in preclinical development and it has additional preclinical mAb discovery programs. The PYXS stock yearly return is shown above.
The yearly return on the PYXS stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2022 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the PYXS annual return calculation with any dividends reinvested as applicable (on ex-dates).
|